AHA Coding Clinic® for HCPCS - 2018 Quarter 1; For Your Information
New HCPCS codes for the reporting of biosimilar products
Effective April 1, 2018, three new HCPCS codes will be available for the reporting of biosimilar products. Currently biosimilar products are reported with HCPCS code Q5102 , Injection, infliximab, biosimilar, 10 mg, which will be discontinued on March 31, 2018. HCPCS code Q5102 will be replaced with HCPCS code Q5103 and Q5104 , effective April 1 2018. Also, beginning April 1 2018, modifiers that describe the manufacturer of a biosimilar product (ie, ZA, ZB, and ZC) will no longer be required for Medicare reporting of HCPCS codes for biosimilar products. The new HCPCS codes and their code descriptors are listed in...
Subscribe or sign in to view the full article.
Article Overview
This article covers April 2018 HCPCS updates related to biosimilar product reporting. It is relevant to coders, billers, and compliance staff who need to track code replacements, new product-specific entries, and associated Medicare reporting changes. The guidance focuses on which HCPCS identifiers are changing and the general reporting context for biosimilar products.
Why This Topic Matters
Biosimilar product reporting can affect claim accuracy, Medicare reporting, and code maintenance workflows. Understanding these HCPCS updates helps practices and billing teams recognize changes in the code set and related modifier reporting requirements.
What You Will Learn
- How HCPCS biosimilar reporting changed effective April 1, 2018
- Which biosimilar-related HCPCS identifiers were introduced, replaced, or discontinued
- How the article frames Medicare reporting changes for biosimilar products
- Which product categories are associated with the updated HCPCS entries
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle teams
- Compliance staff
- Healthcare providers submitting claims
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com